Ernexa Therapeutics (ERNAW) Intangibles (2010 - 2022)

Ernexa Therapeutics (ERNAW) has 13 years of Intangibles data on file, last reported at $6.0 million in Q1 2022.

• Quarterly Intangibles changed 0.17% year-over-year to $6.0 million in Q1 2022, while the trailing twelve-month figure through Mar 2022 was $6.0 million (changed 0.17% YoY) and the FY2021 annual result came in at $6.0 million, changed 0.0% from the prior year.
• Intangibles steadied at $6.0 million in Q1 2022, from $6.0 million in the prior quarter.
• In the past five years, Intangibles ranged from a high of $6.0 million in Q4 2018 to a low of $1.6 million in Q1 2018.
• A 5-year average of $4.3 million and a median of $6.0 million in 2020 frame the typical range for Intangibles.
• Annual changes were most pronounced in 2018 — Intangibles surged 9200.0% — and 2019, when it sank 68.08%.
• Tracing ERNAW's Intangibles over 5 years: stood at $6.0 million in 2018, then sank by 68.08% to $1.9 million in 2019, then soared by 212.79% to $6.0 million in 2020, then changed by 0.0% to $6.0 million in 2021, then increased by 0.17% to $6.0 million in 2022.
• The last three Intangibles figures came in at $6.0 million (Q1 2022), $6.0 million (Q4 2021), and $6.0 million (Q3 2021), per Business Quant data.